Asian Pacific Journal of Cancer Prevention

  • 제14권2호
  • /
  • Pages.1121-1126
  • /
  • 2013
  • /
  • 1513-7368(pISSN)
  • /
  • 2476-762X(eISSN)
아시아태평양암예방학회 (Asian Pacific Journal of Cancer Prevention)
권호 표지
DOI QR코드

DOI QR Code

Carboplatin/5-fluorouracil as an Alternative to Cisplatin/5-Fluorouracil for Metastatic and Recurrent Head and Neck Squamous Cell Carcinoma and Nasopharyngeal Carcinoma

  • Kua, Voon Fong (Department of Clinical Oncology, University Kebangsaan Malaysia Medical Center) ;
  • Ismail, Fuad (Department of Clinical Oncology, University Kebangsaan Malaysia Medical Center) ;
  • Phua, Vincent Chee Ee (Clinical Oncology Unit, Faculty of Medicine, University of Malaya) ;
  • Aslan, Nik Muhd (Department of Clinical Oncology, University Kebangsaan Malaysia Medical Center)
  • 발행 : 2013.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Palliative chemotherapy with cisplatin/5-fluorouracil (5FU) is the commonest regimen employed for metastatic and recurrent head and neck squamous cell carcinoma (SCCHN) and nasopharyngeal carcinoma (NPC). However, this regimen is cumbersome requiring 5 days of admission to hospital. Carboplatin/5FU may be an alternative regimen without compromising survival and response rates. This study aimed to compare the efficacy and toxicity of carboplatin/5FU regimen with the cisplatin/5FU regimen. Materials and Methods: This retrospective study looked at patients who had palliative chemotherapy with either cisplatin/5FU or carboplatin/5FU for metastatic and recurrent SCCHN and NPC. It included patients who were treated at UKMMC from $1^{st}$ January 2004 to $31^{st}$ December 2009 with either palliative IV cispaltin 75 $mg/m^2$ D1 only plus IV 5FU 750 $mg/m^2$ D1-5 infusion or IV Carboplatin AUC 5 D1 only plus IV 5FU 500 $mg/m^2$ D1-2 infusion plus IV 5FU 500 $mg/m^2$ D1-2 bolus. The specific objectives were to determine the efficacy of palliative chemotherapy in terms of overall response rate (ORR), median progression free survival (PFS) and median overall survival (OS) and to evaluate the toxicities of both regimens. Results: A total of 41 patients were eligible for this study. There were 17 in the cisplatin/5FU arm and 24 in the carboplatin/5FU arm. The ORR was 17.7 % for cisplatin/5FU arm and 37.5 % for carboplatin/5FU arm (p-value=0.304). The median PFS was 7 months for cisplatin/5FU and 9 months for carboplatin/5FU (p-value=1.015). The median OS was 10 months for cisplatin/5FU arm and 12 months for carboplatin/5FU arm (p-value=0.110). There were 6 treatment-related deaths (6/41=14.6%), four in the carboplatin/5FU arm (4/24=16.7%) and 2 in the cisplatin/5FU arm (2/17=11.8%). Grade 3 and 4 hematologic toxicity was also more common with carboplatin/5FU group, this difference being predominantly due to grade 3-4 granulocytopenia (41.6% vs. 0), grade 3-4 anemia (37.5% vs. 0) and grade 3-4 thrombocytopenia (16.6% vs. 0). Conclusions: Carboplatin/5FU is not inferior to cisplatin/5FU with regard to its efficacy. However, there was a high rate of treatment-related deaths with both regimens. A better alternative needs to be considered.

키워드

참고문헌

  1. Al-Sarraf M (1988). Head and neck cancer: chemotherapy concepts. Semin Oncol, 15, 70-85.
  2. Boussen H, Cvitkovic E, Wendling JL, et al (1991). Chemotherapy of metastatic and/or recurrent undifferentiated nasopharyngeal carcinoma with cisplatin, bleomycin, and fluorouracil. J Clin Oncol, 9, 1675.
  3. Browman GP, Cronin L (1994). Standard chemotherapy in squamous cell head and neck cancer: what we have learned from randomized trials. Semin Oncol, 21, 311-9.
  4. Calvert AH, Grumbrell LA, Henk MJ (1986). Paraplatin phase II studies in head and neck cancer. Proceedings from the Symposium on Paraplatin. The British Transition; London, England, p25.
  5. Chan ATC, Hsu MM, Goh BC, et al (2005). Multicenter, phase 2 study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol, 23, 3568-76. https://doi.org/10.1200/JCO.2005.02.147
  6. Chitapanarux I, Lorvidhaya V, Kamnerdsupaphon P, et al (2007). Chemoradiation comparing cisplatin versus carboplatin in locally advanced nasopharyngeal cancer: Randomised, non-inferiority, open trial. Eur J of Cancer, 43, 1399-406. https://doi.org/10.1016/j.ejca.2007.03.022
  7. Choo R, Tannock I (1991). Chemotherapy for recurrent or metastatic carcinoma of the nasopharynx. A review of the princess margaret hospital experience. Cancer, 68, 2120. https://doi.org/10.1002/1097-0142(19911115)68:10<2120::AID-CNCR2820681005>3.0.CO;2-7
  8. Clavel M, Vermorken JB, Cognetti F, et al (1994). Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine versus cisplatin (CABO) and cisplatin+5FU versus cisplatin in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase II study of the EORTC head and neck cancer cooperative group. Ann Oncol, 5, 521-6.
  9. Forastiere AA, Metch B, Schuller DE, et al (1992). Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous cell carcinoma of the head and neck : a Southwest Oncology Group study. J Clin Oncol, 10, 1245-51.
  10. Forastiere AA, Natale RB, Takasugi BJ, et al (1987). A phase I-II trial of carboplatin and 5FU combination chemotherapy in advanced carcinoma of the head and neck. J Clin Oncol, 5, 190-6.
  11. Forastiere AA , Takasugi BJ, Baker SR et al (1997). High dose cisplatin in advanced head and neck cancer. Cancer chemother Pharmacol, 19, 155-8.
  12. Grose WE, Lehane DE, Dixon DO, et al (1985). Comparison of methotrexate and cisplatin for patients with advanced squamous cell carcinoma of the head and neck region: a Southwest oncology group study. Cancer Treat Rep, 69, 577-81.
  13. Hansen RM, Ryan L, Anderson T, et al (1996). Phase III study of bolus versus infusional 5 Fluorouracil with or without cisplatin in advanced colorectal cancer. Ann Oncol, 88, 668-74.
  14. Havlin KA, Kuhn JG, Myers JW, et al (1989). High-dose cisplatin for locally advanced or metastatic head and neck cancer. A phase II pilot study. Cancer, 63, 423-7. https://doi.org/10.1002/1097-0142(19890201)63:3<423::AID-CNCR2820630304>3.0.CO;2-C
  15. Hong WK, Schaefer S, Issell B, et al (1983). A prospective randomized trial of methotrexate versus cisplatin in the treatment of recurrent squamous cell carcinoma of the head and neck. Cancer, 52, 206-10. https://doi.org/10.1002/1097-0142(19830715)52:2<206::AID-CNCR2820520204>3.0.CO;2-J
  16. Inuyama Y, Togawa K, Morita, et al (1998). Phase II study of carboplatin in head and neck cancer. Gan-To-Kagaku-Ryoho, 15, 2131-8.
  17. Jacobs C, Bertino JR, Goffinet DR, et al (1978). 24-hour infusion of cisplatinum in head and neck cancers. Cancer, 42, 2135-40. https://doi.org/10.1002/1097-0142(197811)42:5<2135::AID-CNCR2820420508>3.0.CO;2-W
  18. Jacobs C, Lyman G, Velez-Garcia E, et al (1990). Liverpool head and neck oncology group. A phase III randomized trial of cisplatinum, methotrexate, cisplatinum +methotrexate and cisplatinum + 5FU in end stage squamous cell carcinoma of the head and neck. Liverpool head and neck oncology group. Br J Cancer, 61, 311-5. https://doi.org/10.1038/bjc.1990.59
  19. Jacobs C, Lyman G, Velez-Garcia E, et al (1992). A phase III randomized study comparing cisplatin and fluorouracil as single agent and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol, 10, 257-63.
  20. Kirkwood JM, Canellos GP, Ervin TJ, et al (1981). Increased therapeutic index using moderate dose methotrexate and leucovorin twice weekly vs. weekly high dose methotrexate-leucovorin in patients with advanced squamous carcinoma of the head and neck: a safe new effective regimen. Cancer, 47, 2414-21. https://doi.org/10.1002/1097-0142(19810515)47:10<2414::AID-CNCR2820471016>3.0.CO;2-W
  21. Kish JA, Ensley JF, Jacobs J, et al (1885). A randomized trial of cisplatin (CACP) + 5Fluorouracil (5FU) infusion and CACP +5FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer, 56, 2740-4.
  22. Lane M, Moore JE, Levin, et al (1968). Methotrexate therapy for squamous cell carcinoma of the head and neck. Intermittent intravenous dose program. JAMA, 204, 561-4. https://doi.org/10.1001/jama.1968.03140200001001
  23. Leone LA, Albala MM, Rege VB (1968). Treatment of carcinoma of the head and neck with intravenous methotrexate. Cancer; 21, 828-837. https://doi.org/10.1002/1097-0142(196805)21:5<828::AID-CNCR2820210507>3.0.CO;2-Q
  24. Leung SS, Wee J, Tay MH, et al (2004). Paclitaxel, carboplatin and gemcitabine in metastatic nasopharyngeal carcinoma. Cancer, 103, 569-75.
  25. Licitra L, Marchini S, Spinazze S, et al (1991). Cisplatin in advanced salivary gland carcinoma. A phase II study of 25 patients. Cancer, 68, 1874-7. https://doi.org/10.1002/1097-0142(19911101)68:9<1874::AID-CNCR2820680904>3.0.CO;2-S
  26. Li YH, Wang FH, Jiang WQ, et al (2008). Phase II study of capecitabine and cisplatin combination as first line chemotherapy in Chinese patients with metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol, 62, 539-44. https://doi.org/10.1007/s00280-007-0641-2
  27. Morton RP, Rugman F, Dorman EB, et al (1985). Cisplatinum and bleomycin for advanced of recurrent squamous cell carcinoma of the head and neck: a randomized factorial phase III controlled trial. Cancer Chemother Pharmacol, 15, 283-9.
  28. Olver IN, Dalley D, Woods R, et al (1989). Carboplatin and continuous infusion 5-Fluorouracil for advanced head and neck cancer. Eur J Cancer Clin Oncol, 25, 173-6. https://doi.org/10.1016/0277-5379(89)90004-7
  29. Papac R, Minor DR, Rudnik S, et al (1978). Controlled trial of methotrexate and bacillus clamette-guerin therapy for advanced head and neck cancer. Cancer Res, 38, 3150-3.
  30. Sako K, Razack MS, Kalmins I (1978). Chemotherapy for advanced and recurrent squamous cell carcinoma of the head and neck with high and low dose cis-diamminedichloroplatinum. Ann J Surg, 136, 529-33. https://doi.org/10.1016/0002-9610(78)90276-3
  31. Taamma A, Fandi A, Azli N, et al (1999). Phase II trial of chemotherapy with 5-fluorouracil, bleomycin, epirubicin, and cisplatin for patients with locally advanced, metastatic, or recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer, 86, 1101. https://doi.org/10.1002/(SICI)1097-0142(19991001)86:7<1101::AID-CNCR2>3.0.CO;2-R
  32. Twelves C, Wong A, Nowacki MP, et al (2005). Capecitabine as adjuvant treatment for stage III colon cancer (X-ACT trial). N Engl J Med, 352, 2696-704. https://doi.org/10.1056/NEJMoa043116
  33. Urba SG, Forastiere AA (1989). Systemic therapy of head and neck cancer: Most effective agents, areas of promise. Oncology, 3, 79-88.
  34. Veronesi A, Zagonel V, Tirelli U, et al (1985). High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: a randomized study. J Clin Oncol, 3, 1105-8.
  35. Vogl SE, Schoenfeld DA, Kaplan BH, et al (1985). A randomized prospective comparison of methotrexate with a combination of methotrexate, bleomycin, and cisplatin in head and neck cancer. Cancer, 56, 432-42. https://doi.org/10.1002/1097-0142(19850801)56:3<432::AID-CNCR2820560304>3.0.CO;2-X
  36. Williams SD, Velez-Gracia E, Essence I, et al (1986). Chemotherapy for head and neck cancer. Comparison of cisplatin+vinblastine+bleomycin versus methotrexate. Cancer, 57, 18-23. https://doi.org/10.1002/1097-0142(19860101)57:1<18::AID-CNCR2820570106>3.0.CO;2-V
  37. Writes RE (1980). Chemotherapy of head and neck cancer. Otolaryngol Clin North Am, 13, 515-20.
  38. Writes R, Heller K, Randolph V, et al (1979). Cis-dichlorodiammineplatinum(II)-based chemotherapy as initial treatment of advanced head and neck cancer. Cancer Treat Rep, 63, 1533-8.
  39. Yeo W, Leung TW, Leung SF, et al (1996). Phase II study of the combination of carboplatin and 5-fluorouracil in metastatic nasopharyngeal carcinoma. Cancer Chemother Pharmacol, 38, 466. https://doi.org/10.1007/s002800050512
  40. Yon YW, Park YH, Ahn MJ, et al (2011). A phase II study of combination chemotherapy with capecitabine and cisplatin in patients with metastatic or recurrent squamous cell carcinoma of head and neck. Ann Oncol, 22, 417-23. https://doi.org/10.1093/annonc/mdq355

피인용 문헌

  1. Reirradiation with Robotic Stereotactic Body Radiotherapy for Recurrent Nasopharyngeal Carcinoma vol.15, pp.8, 2014, https://doi.org/10.7314/APJCP.2014.15.8.3561
  2. Selective Radiotherapy after Distant Metastasis of Nasopharyngeal Carcinoma Treated with Dose-Dense Cisplatin plus Fluorouracil vol.16, pp.14, 2015, https://doi.org/10.7314/APJCP.2015.16.14.6011
  3. Organic nanoparticle systems for spatiotemporal control of multimodal chemotherapy vol.14, pp.3, 2017, https://doi.org/10.1080/17425247.2016.1218464
  4. Concurrent 5-fluorouracil and carboplatin for the treatment of canine carcinomas pp.14765810, 2018, https://doi.org/10.1111/vco.12426